TGTX Q4 2025 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$193M+78.0% YoY

Gross Profit

$154M80.2% margin

Operating Income

$50M26.2% margin

Net Income

$23M12.0% margin

EPS (Diluted)

$0.14

QoQ Revenue Growth

+19.1%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

$20M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$415M

Stockholders' Equity

$648M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$193M	$108M	+78.0%
Gross Profit	$154M	$93M	+66.4%
Operating Income	$50M	$30M	+68.6%
Net Income	$23M	$23M	-1.3%

Revenue Segments

Product

$189M96%

Royalty

$5M3%

Other Revenue

$3M2%